XML 59 R36.htm IDEA: XBRL DOCUMENT
v3.25.2

Segment Information (Tables) | 12 Months Ended
--- | ---
Jun. 30, 2025
Segment Reporting [Abstract] |
Summary of Financial Data for Development of Pharmaceutical Products Segments | The following table summarizes our financial data for the development of pharmaceutical products segment:
|  | For the Fiscal Year Ended June 30, |
|  | 2025 |  |  | 2024 |
Revenues |  | $ | — |  |  | $ | 65,297 |
Operating and other (income) expense |  |  |  |  |  |
Employee expenses |  |  | 9,293 |  |  |  | 13,207 |
Other segment expenses(1) |  |  | 2,647 |  |  |  | 9,946 |
Professional fees |  |  | 2,754 |  |  |  | 4,092 |
Legal fees |  |  | 1,723 |  |  |  | 3,397 |
Impairment of long-lived assets |  |  | — |  |  |  | 10,899 |
Fees paid on behalf of a related party |  |  | — |  |  |  | 1,118 |
voruciclib |  |  | 801 |  |  |  | 3,413 |
ME-344 |  |  | 253 |  |  |  | 4,724 |
Gain on disposition of a non-financial asset |  |  | (500 | ) |  |  | — |
Interest and dividend income |  |  | (1,026 | ) |  |  | (3,277 | )
Total operating and other (income) expense |  |  | 15,945 |  |  |  | 47,519 |
Total segment costs (loss) income and net (loss) income |  | $ | (15,945 | ) |  | $ | 17,778 |
________ (1) Includes product development costs associated with zandelisib determined to be immaterial for both periods presented, occupancy costs (including rent and utilities), share-based compensation costs, depreciation expense, administrative costs, travel and business taxes.

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration